These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 23794116)

  • 1. Growth hormone values after an oral glucose load do not add clinically useful information in patients with acromegaly on long-term somatostatin receptor ligand treatment.
    Reimondo G; Bondanelli M; Ambrosio MR; Grimaldi F; Zaggia B; Zatelli MC; Allasino B; Laino F; Aroasio E; Termine A; Conton P; Paoletta A; Demenis E; Uberti ED; Terzolo M
    Endocrine; 2014 Feb; 45(1):122-7. PubMed ID: 23794116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of biochemical control of acromegaly during treatment with somatostatin analogues by oral glucose load and insulin-like growth factor I.
    Scacchi M; Carzaniga C; Vitale G; Fatti LM; Pecori Giraldi F; Andrioli M; Cattaneo A; Cavagnini F
    J Endocrinol Invest; 2011 Oct; 34(9):e291-5. PubMed ID: 21697649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of growth hormone receptor d3 and full-length isoforms on biochemical treatment outcomes in acromegaly.
    Bianchi A; Giustina A; Cimino V; Pola R; Angelini F; Pontecorvi A; De Marinis L
    J Clin Endocrinol Metab; 2009 Jun; 94(6):2015-22. PubMed ID: 19336510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly.
    Karavitaki N; Botusan I; Radian S; Coculescu M; Turner HE; Wass JA
    Clin Endocrinol (Oxf); 2005 Mar; 62(3):282-8. PubMed ID: 15730408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly.
    Carmichael JD; Bonert VS; Mirocha JM; Melmed S
    J Clin Endocrinol Metab; 2009 Feb; 94(2):523-7. PubMed ID: 19033371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of disease activity in treated acromegalic patients using a sensitive GH assay: should we achieve strict normal GH levels for a biochemical cure?
    Costa AC; Rossi A; Martinelli CE; Machado HR; Moreira AC
    J Clin Endocrinol Metab; 2002 Jul; 87(7):3142-7. PubMed ID: 12107214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discordant nadir GH after oral glucose and IGF-I levels on treated acromegaly: refining the biochemical markers of mild disease activity.
    Elias PC; Lugao HB; Pereira MC; Machado HR; Castro Md; Moreira AC
    Horm Metab Res; 2010 Jan; 42(1):50-5. PubMed ID: 19798623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Growth hormone responses to oral glucose and intravenous thyrotropin-releasing hormone in acromegalic patients treated by slow-release lanreotide.
    Díez JJ; Iglesias P; Gómez-Pan A
    J Endocrinol Invest; 2001 May; 24(5):303-9. PubMed ID: 11407648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discordant growth hormone and IGF-1 levels post pituitary surgery in patients with acromegaly naïve to medical therapy and radiation: what to follow, GH or IGF-1 values?
    Brzana JA; Yedinak CG; Delashaw JB; Gultelkin HS; Cook D; Fleseriu M
    Pituitary; 2012 Dec; 15(4):562-70. PubMed ID: 22183781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gender and age in the biochemical assessment of cure of acromegaly.
    Freda PU; Landman RE; Sundeen RE; Post KD
    Pituitary; 2001 Aug; 4(3):163-71. PubMed ID: 12138989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of acromegaly with SS analogues: should GH and IGF-I target levels be lowered to assert a tight control of the disease?
    Cozzi R; Attanasio R; Grottoli S; Pagani G; Loli P; Gasco V; Pedroncelli AM; Montini M; Ghigo E
    J Endocrinol Invest; 2004 Dec; 27(11):1040-7. PubMed ID: 15754736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measurement of basal growth hormone (GH) is a useful test of disease activity in treated acromegalic patients.
    Jayasena CN; Wujanto C; Donaldson M; Todd JF; Meeran K
    Clin Endocrinol (Oxf); 2008 Jan; 68(1):36-41. PubMed ID: 18088288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs.
    Petrossians P; Borges-Martins L; Espinoza C; Daly A; Betea D; Valdes-Socin H; Stevenaert A; Chanson P; Beckers A
    Eur J Endocrinol; 2005 Jan; 152(1):61-6. PubMed ID: 15762188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medical therapy in patients with acromegaly: predictors of response and comparison of efficacy of dopamine agonists and somatostatin analogues.
    Sherlock M; Fernandez-Rodriguez E; Alonso AA; Reulen RC; Ayuk J; Clayton RN; Holder G; Sheppard MC; Bates A; Stewart PM
    J Clin Endocrinol Metab; 2009 Apr; 94(4):1255-63. PubMed ID: 19158203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medical treatment of acromegaly: comorbidities and their reversibility by somatostatin analogs.
    Tolis G; Angelopoulos NG; Katounda E; Rombopoulos G; Kaltzidou V; Kaltsas D; Protonotariou A; Lytras A
    Neuroendocrinology; 2006; 83(3-4):249-57. PubMed ID: 17047390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acromegaly.
    Scacchi M; Cavagnini F
    Pituitary; 2006; 9(4):297-303. PubMed ID: 17077948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting either GH or IGF-I during somatostatin analogue treatment in patients with acromegaly: a randomized multicentre study.
    Dal J; Klose M; Heck A; Andersen M; Kistorp C; Nielsen EH; Bollerslev J; Feldt-Rasmussen U; Jørgensen JOL
    Eur J Endocrinol; 2018 Jan; 178(1):65-74. PubMed ID: 28993415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin-like growth factor-I correlates more closely than growth hormone with insulin resistance and glucose intolerance in patients with acromegaly.
    Niculescu D; Purice M; Coculescu M
    Pituitary; 2013 Jun; 16(2):168-74. PubMed ID: 22562529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dynamic tests for the diagnosis and assessment of treatment efficacy in acromegaly.
    Cazabat L; Souberbielle JC; Chanson P
    Pituitary; 2008; 11(2):129-39. PubMed ID: 18418712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term safety and efficacy of depot long-acting somatostatin analogs for the treatment of acromegaly.
    Ayuk J; Stewart SE; Stewart PM; Sheppard MC
    J Clin Endocrinol Metab; 2002 Sep; 87(9):4142-6. PubMed ID: 12213862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.